J.Safra Asset Management Corp Cytokinetics Inc Transaction History
J.Safra Asset Management Corp
- $1.31 Billion
- Q2 2025
A detailed history of J.Safra Asset Management Corp transactions in Cytokinetics Inc stock. As of the latest transaction made, J.Safra Asset Management Corp holds 3,381 shares of CYTK stock, worth $123,846. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,381
Previous 2,870
17.8%
Holding current value
$123,846
Previous $115,000
3.48%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding CYTK
# of Institutions
398Shares Held
128MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$537 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$434 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$365 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$293 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$223 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.45B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...